Pharmacology and Therapeutics

Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench

  1. Jhih-Yuan Shih1,
  2. Yu-Wen Lin1,
  3. Sudeshna Fisch2,
  4. Juei-Tang Cheng3,
  5. Nai-Wen Kang4,
  6. Chon-Seng Hong1,
  7. Zhih-Cherng Chen1 and
  8. Wei-Ting Chang1,5,6⇑
  1. 1Division of Cardiology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan
  2. 2Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
  3. 3Department of Research, Chi-Mei Medical Center, Tainan, Taiwan
  4. 4Division of Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan
  5. 5Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
  6. 6Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan
  1. Corresponding author: Wei-Ting Chang, cmcvecho2{at}gmail.com
Diabetes 2021 Jan; 70(1): 262-267. https://doi.org/10.2337/db20-0840

Data supplements

  • Supplemental material, Chang, et al.

    Supplemental material is available at https://doi.org/10.2337/figshare.13122956.
    Back to top
    View Selected Citations (0)
    Article Alerts
    Email Article
    Citation Tools
    Add to Selected Citations

    Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench
    Jhih-Yuan Shih, Yu-Wen Lin, Sudeshna Fisch, Juei-Tang Cheng, Nai-Wen Kang, Chon-Seng Hong, Zhih-Cherng Chen, Wei-Ting Chang
    Diabetes Jan 2021, 70 (1) 262-267; DOI: 10.2337/db20-0840
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

    Jump to section

    Subjects